{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:03:00Z","timestamp":1790809380470,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":143,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004789","name":"John Fell Fund, University of Oxford","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004789","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01467-z","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:37:26Z","timestamp":1778517446000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intranasal boosting enhances genital tract T cell immunity following ChAdOx1\/MVA hrHPV therapeutic vaccination"],"prefix":"10.1038","volume":"11","author":[{"given":"Gemma","family":"Hancock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"L\u00f3pez-Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Dorrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"1467_CR1","doi-asserted-by":"publisher","unstructured":"zur Hausen, H. Human papillomaviruses and their possible role in squamous cell carcinomas. 1\u201330. https:\/\/doi.org\/10.1007\/978-3-642-66800-5_1 (1977).","DOI":"10.1007\/978-3-642-66800-5_1"},{"key":"1467_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1467_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1056\/NEJMra2404457","volume":"392","author":"KS Tewari","year":"2025","unstructured":"Tewari, K. S. Cervical cancer. N. Engl. J. Med. 392, 56\u201371 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1467_CR4","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1038\/s41591-022-02109-2","volume":"28","author":"F Guida","year":"2022","unstructured":"Guida, F. et al. Global and regional estimates of orphans attributed to maternal cancer mortality in 2020. Nat. Med. 28, 2563\u20132572 (2022).","journal-title":"Nat. Med"},{"key":"1467_CR5","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","author":"J Paavonen","year":"2007","unstructured":"Paavonen, J. et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369, 2161\u20132170 (2007).","journal-title":"Lancet"},{"key":"1467_CR6","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/ijc.25940","volume":"129","author":"RM Haupt","year":"2011","unstructured":"Haupt, R. M. et al. Impact of an HPV6\/11\/16\/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16\/18 infection. Int. J. Cancer 129, 2632\u20132642 (2011).","journal-title":"Int. J. Cancer"},{"key":"1467_CR7","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/j.1471-0528.2008.01936.x","volume":"115","author":"YL Woo","year":"2008","unstructured":"Woo, Y. L. et al. Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis. BJOG 115, 1616\u20131621 (2008).","journal-title":"BJOG"},{"key":"1467_CR8","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/eji.202249823","volume":"52","author":"M Cokari\u0107 Brdov\u010dak","year":"2022","unstructured":"Cokari\u0107 Brdov\u010dak, M. et al. ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination. Eur. J. Immunol. 52, 936\u2013945 (2022).","journal-title":"Eur. J. Immunol."},{"key":"1467_CR9","doi-asserted-by":"publisher","unstructured":"Tang, J. et al. Therapeutic DNA vaccines against hpv-related malignancies: promising leads from clinical trials. Viruses 14. https:\/\/doi.org\/10.3390\/v14020239 (2022).","DOI":"10.3390\/v14020239"},{"key":"1467_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00485-x","volume":"7","author":"SA Hameed","year":"2022","unstructured":"Hameed, S. A., Paul, S., Dellosa, G. K. Y., Jaraquemada, D. & Bello, M. B. Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies. NPJ Vaccines 7, 71 (2022).","journal-title":"NPJ Vaccines"},{"key":"1467_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127356","volume":"61","author":"A Tscherne","year":"2025","unstructured":"Tscherne, A. & Krammer, F. A review of currently licensed mucosal COVID-19 vaccines. Vaccine 61, 127356 (2025).","journal-title":"Vaccine"},{"key":"1467_CR12","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","volume":"26","author":"VP Chavda","year":"2021","unstructured":"Chavda, V. P., Vora, L. K., Pandya, A. K. & Patravale, V. B. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug Discov. Today 26, 2619\u20132636 (2021).","journal-title":"Drug Discov. Today"},{"key":"1467_CR13","doi-asserted-by":"publisher","unstructured":"Beavis, A. C. et al. Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa. Front. Immunol. 14. https:\/\/doi.org\/10.3389\/fimmu.2023.1186478 (2023).","DOI":"10.3389\/fimmu.2023.1186478"},{"key":"1467_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.vaccine.2006.07.011","volume":"25","author":"APD de Souza","year":"2007","unstructured":"de Souza, A. P. D. et al. Genital CD8+ T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus. Vaccine 25, 109\u2013116 (2007).","journal-title":"Vaccine"},{"key":"1467_CR15","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.4049\/jimmunol.180.4.2504","volume":"180","author":"Z Li","year":"2008","unstructured":"Li, Z. et al. Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge. J. Immunol. 180, 2504\u20132513 (2008).","journal-title":"J. Immunol."},{"key":"1467_CR16","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/ijc.31166","volume":"142","author":"N \u00c7uburu","year":"2018","unstructured":"\u00c7uburu, N. et al. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8 + T cell responses against HPV16 oncoproteins. Int. J. Cancer 142, 1467\u20131479 (2018).","journal-title":"Int. J. Cancer"},{"key":"1467_CR17","doi-asserted-by":"publisher","unstructured":"P\u00e9rez, P. et al. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection. Front. Immunol. 13. https:\/\/doi.org\/10.3389\/fimmu.2022.995235 (2022).","DOI":"10.3389\/fimmu.2022.995235"},{"key":"1467_CR18","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.4049\/jimmunol.172.10.6209","volume":"172","author":"MM Gherardi","year":"2004","unstructured":"Gherardi, M. M., Pe\u0301rez-Jime\u0301nez, E., Na\u0301jera, J. L. & Esteban, M. Induction of HIV Immunity in the Genital Tract After Intranasal Delivery of a MVA Vector: enhanced Immunogenicity After DNA Prime-Modified Vaccinia Virus Ankara Boost Immunization Schedule. J. Immunol. 172, 6209\u20136220 (2004).","journal-title":"J. Immunol."},{"key":"1467_CR19","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1016\/j.vaccine.2013.03.021","volume":"31","author":"MG Cottingham","year":"2013","unstructured":"Cottingham, M. G. & Carroll, M. W. Recombinant MVA vaccines: dispelling the myths. Vaccine 31, 4247\u20134251 (2013).","journal-title":"Vaccine"},{"key":"1467_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55014-z","volume":"9","author":"G Hancock","year":"2019","unstructured":"Hancock, G. et al. A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins. Sci. Rep. 9, 18713 (2019).","journal-title":"Sci. Rep."},{"key":"1467_CR21","first-page":"228","volume":"53","author":"L Cui","year":"2014","unstructured":"Cui, L. et al. Transcervical embryo transfer in mice. J. Am. Assoc. Lab Anim. Sci. 53, 228\u2013231 (2014).","journal-title":"J. Am. Assoc. Lab Anim. Sci."},{"key":"1467_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.0105-2896.2006.00395.x","volume":"211","author":"A Harari","year":"2006","unstructured":"Harari, A. et al. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol. Rev. 211, 236\u2013254 (2006).","journal-title":"Immunol. Rev."},{"key":"1467_CR23","doi-asserted-by":"publisher","first-page":"e0128714","DOI":"10.1371\/journal.pone.0128714","volume":"10","author":"A Boyd","year":"2015","unstructured":"Boyd, A. et al. Pathogen-specific T cell polyfunctionality is a correlate of T cell efficacy and immune protection. PLoS ONE 10, e0128714 (2015).","journal-title":"PLoS ONE"},{"key":"1467_CR24","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1084\/jem.20070784","volume":"204","author":"JR Almeida","year":"2007","unstructured":"Almeida, J. R. et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204, 2473\u20132485 (2007).","journal-title":"J. Exp. Med."},{"key":"1467_CR25","doi-asserted-by":"publisher","first-page":"10134","DOI":"10.1128\/JVI.00647-14","volume":"88","author":"F Graw","year":"2014","unstructured":"Graw, F. & Regoes, R. R. Predicting the impact of CD8 + T cell polyfunctionality on HIV disease progression. J. Virol. 88, 10134\u201310145 (2014).","journal-title":"J. Virol."},{"key":"1467_CR26","doi-asserted-by":"publisher","first-page":"7107","DOI":"10.4049\/jimmunol.1002756","volume":"185","author":"CL Trimble","year":"2010","unstructured":"Trimble, C. L. et al. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J. Immunol. 185, 7107\u20137114 (2010).","journal-title":"J. Immunol."},{"key":"1467_CR27","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","volume":"386","author":"CL Trimble","year":"2015","unstructured":"Trimble, C. L. et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386, 2078\u20132088 (2015).","journal-title":"Lancet"},{"key":"1467_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ygyno.2005.11.039","volume":"102","author":"S Monnier-Benoit","year":"2006","unstructured":"Monnier-Benoit, S. et al. Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix. Gynecol. Oncol. 102, 22\u201331 (2006).","journal-title":"Gynecol. Oncol."},{"key":"1467_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.it.2006.03.007","volume":"27","author":"JR Mora","year":"2006","unstructured":"Mora, J. R. & von Andrian, U. H. T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol. 27, 235\u2013243 (2006).","journal-title":"Trends Immunol."},{"key":"1467_CR30","doi-asserted-by":"publisher","first-page":"a029124","DOI":"10.1101\/cshperspect.a029124","volume":"10","author":"AJ McMichael","year":"2018","unstructured":"McMichael, A. J. Is a human CD8 T-cell vaccine possible, and if so, what would it take? Cold Spring Harb. Perspect. Biol. 10, a029124 (2018).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1467_CR31","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1016\/j.ymthe.2024.10.016","volume":"32","author":"G Laghlali","year":"2024","unstructured":"Laghlali, G. et al. Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime\/intranasal protein boost vaccination with a combination adjuvant. Mol. Ther. 32, 4448\u20134466 (2024).","journal-title":"Mol. Ther."},{"key":"1467_CR32","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.4049\/jimmunol.2200297","volume":"210","author":"MM Shamseldin","year":"2023","unstructured":"Shamseldin, M. M. et al. Prime-pull immunization of mice with a BcfA-adjuvanted vaccine elicits sustained mucosal immunity that prevents SARS-CoV-2 infection and pathology. J. Immunol. 210, 1257\u20131271 (2023).","journal-title":"J. Immunol."},{"key":"1467_CR33","doi-asserted-by":"publisher","unstructured":"Hirsch A. H., et al. Heterologous prime-pull mucosal vaccination with an adjuvanted RBD vaccine elicits robust IgA production and protects against SARS-CoV-2. Front. Immunol. 16. https:\/\/doi.org\/10.3389\/fimmu.2025.1673460 (2025).","DOI":"10.3389\/fimmu.2025.1673460"},{"key":"1467_CR34","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.4049\/jimmunol.1800219","volume":"202","author":"N \u00c7uburu","year":"2019","unstructured":"\u00c7uburu, N. et al. A prime-pull-amplify vaccination strategy to maximize induction of circulating and genital-resident intraepithelial CD8+ memory T cells. J. Immunol. 202, 1250\u20131264 (2019).","journal-title":"J. Immunol."},{"key":"1467_CR35","doi-asserted-by":"publisher","unstructured":"Lorenzen E., et al. Intramuscular priming and intranasal boosting induce strong genital immunity through secretory IgA in minipigs infected with chlamydia trachomatis. Front. Immunol. 6. https:\/\/doi.org\/10.3389\/fimmu.2015.00628 (2015).","DOI":"10.3389\/fimmu.2015.00628"},{"key":"1467_CR36","doi-asserted-by":"publisher","unstructured":"Tang J., et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci. Immunol.7. https:\/\/doi.org\/10.1126\/sciimmunol.add4853 (2022).","DOI":"10.1126\/sciimmunol.add4853"},{"key":"1467_CR37","doi-asserted-by":"publisher","unstructured":"Tang J., Sun J. From blood to mucosa. Sci. Transl. Med. 16. https:\/\/doi.org\/10.1126\/scitranslmed.ads6271 (2024).","DOI":"10.1126\/scitranslmed.ads6271"},{"key":"1467_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113956","volume":"178","author":"HM VanBenschoten","year":"2021","unstructured":"VanBenschoten, H. M. & Woodrow, K. A. Vaginal delivery of vaccines. Adv. Drug Deliv. Rev. 178, 113956 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1467_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/COH.0000000000000232","volume":"11","author":"J-AS Passmore","year":"2016","unstructured":"Passmore, J.-A. S., Jaspan, H. B. & Masson, L. Genital inflammation, immune activation and risk of sexual HIV acquisition. Curr. Opin. HIV AIDS 11, 156\u2013162 (2016).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1467_CR40","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/cid\/civ298","volume":"61","author":"L Masson","year":"2015","unstructured":"Masson, L. et al. Genital inflammation and the risk of HIV acquisition in women. Clin. Infect. Dis. 61, 260\u2013269 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"1467_CR41","doi-asserted-by":"publisher","unstructured":"Hellner K. et al. A Phase 1b\/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-Risk Human Papillomavirus Vaccine in Women with Low-grade Cervical Lesions. Clin Infect Dis. ciaf658 https:\/\/doi.org\/10.1093\/cid\/ciaf658 (2025)","DOI":"10.1093\/cid\/ciaf658"},{"key":"1467_CR42","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nrmicro2240","volume":"8","author":"SJ Draper","year":"2010","unstructured":"Draper, S. J. & Heeney, J. L. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol 8, 62\u201373 (2010).","journal-title":"Nat. Rev. Microbiol"},{"key":"1467_CR43","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3390\/vaccines10081367","volume":"10","author":"T Ura","year":"2022","unstructured":"Ura, T. et al. Current vaccine platforms in enhancing T-cell response. Vaccines 10, 1367 (2022).","journal-title":"Vaccines"},{"key":"1467_CR44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines \u2014 a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1467_CR45","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3390\/vaccines12060670","volume":"12","author":"A Toniolo","year":"2024","unstructured":"Toniolo, A., Maccari, G. & Camussi, G. mRNA technology and mucosal immunization. Vaccines 12, 670 (2024).","journal-title":"Vaccines"},{"key":"1467_CR46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","volume":"65","author":"N Pardi","year":"2020","unstructured":"Pardi, N., Hogan, M. J. & Weissman, D. Recent advances in mRNA vaccine technology. Curr. Opin. Immunol. 65, 14\u201320 (2020).","journal-title":"Curr. Opin. Immunol."},{"key":"1467_CR47","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature11522","volume":"491","author":"H Shin","year":"2012","unstructured":"Shin, H. & Iwasaki, A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 491, 463\u2013467 (2012).","journal-title":"Nature"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01467-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01467-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01467-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:28:35Z","timestamp":1790807315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01467-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1467"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01467-z","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no financial or non-financial conflict of interest to declare in relation with this manuscript. K.H., G.H. and C.L.C. are employees of the University of Oxford. L.D. is an employee of Immunocore and TE is consulting for Barinthus Biotherapeutics. Author K.H. is a Guest Editor of npj Vaccines Collection \u2018Therapeutic HPV Vaccines\u2019. They were not involved in the journal\u2019s review of, or decisions related to, this manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"182"}}